Investigation of Migraine

Year : 2024 | Volume :14 | Issue : 01 | Page : 38-45

Vaishnavi D Patil

Sachin R. Gosavi

  1. Student Ahinsa Institute of Pharmacy, Dondaicha Maharashtra India
  2. Student Ahinsa Institute of Pharmacy, Dondaicha Maharashtra India


Individual’s medical history, and any potential side effects that may occur. It is also important to consult with a healthcare provider before beginning any new treatment plan, as they can provide guidance on the best course of action based on the individual’s specific needs and circumstances. In addition to medication, individuals with migraines can explore various treatment avenues. Lifestyle modifications, such as incorporating regular exercise, maintaining a healthy diet, managing stress through relaxation techniques, and ensuring adequate sleep, are all vital components to enhance overall well-being and potentially reduce migraine frequency and intensity. These may encompass various stress management techniques like meditation or yoga, dietary modifications such as avoiding trigger foods, and incorporating regular exercise into one’s routine. Additionally, alternative therapies like acupuncture and biofeedback have emerged as promising adjuncts to conventional treatments in alleviating migraine symptoms, offering patients additional avenues for relief and a more comprehensive approach to managing their condition. Effectively managing migraines necessitates a holistic strategy that considers the individual’s overall well-being and habits. This comprehensive approach involves addressing not only the physical symptoms but also the mental and emotional aspects, lifestyle factors, and any underlying health conditions to achieve optimal results in migraine management. By staying informed about current trends and developments in migraine treatment, individuals can work with their healthcare providers to create a personalized treatment plan that effectively manages their symptoms and improves their quality of life.

Keywords: Analysis of acute Migraine, Chronic migraine, with aura and without aura, Headache, Medication overuse headache.

[This article belongs to Research & Reviews: A Journal of Pharmacology(rrjop)]

How to cite this article: Vaishnavi D Patil, Sachin R. Gosavi. Investigation of Migraine. Research & Reviews: A Journal of Pharmacology. 2024; 14(01):38-45.
How to cite this URL: Vaishnavi D Patil, Sachin R. Gosavi. Investigation of Migraine. Research & Reviews: A Journal of Pharmacology. 2024; 14(01):38-45. Available from:


  1. Migraine and other headache disorders. Published March 6, 2024. Accessed March 20, 2024.
  2. Gordon-smith K. et al. Rapid cycling as a feature of bipolar disorder and comorbid migraine. J Affect Disord [Internet]. Elsevier; 2015; 175: 320–4. Available from:
  3. Arnold M. Headache classification committee of the international headache society (IHS) the international classification of headache disorders. Cephalalgia. 2018;38(1):1-211.
  4. Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, (beta version). Cephalalgia. 2013 Jul;33(9):629-808.
  5. Rasmussen, B. K., Jensen, R., Schroll, M. &Olesen, J.Epidemiology of headache in a general population–aprevalence study. Clin. Epidemiol. 44(11), 1147–1157(1991).
  6. Olesen J. The international classification of headache disorders. Headache: The Journal of Head and Face Pain. 2008 May;48(5):691-3.
  7. Serrano, D. et al. Fluctuations in episodic and chronic migraine status over the course of 1 year: implicationsfor diagnosis, treatment and clinical trial design. Headache Pain 18, 101 (2017).
  8. Silberstein, S.D. et al. (2002) Headache in Clinical Practice (2nd edn), Taylor & Francis
  9. Lance JW, Goadsby PJ. Mechanism and management of headache. 6thed. Boston: Butterworth–Heinemann, 1998.
  10. Silberstein SD, Lipton RB, Goadsby PJ. Headache in clinical practice. Oxford, England: Isis Medical Media, 1998.
  11. Headache Classification Committee of the International Headache Society (HIS). The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013;33(9): 629-808.
  12. Charles A (2013) Migraine: a brain state. Current opinion in neurology 26(3):235–239
  13. Rasmussen BK, Olesen J. Migraine with aura and migraine without aura: an epidemiological study. Cephalalgia. 1992;12(4):221-228.
  14. Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2017;97(2):553–622. doi: 10.1152/physrev.00034.2015.
  15. Akerman S, Holland PR, Goadsby PJ. Diencephalic and brainstem mechanisms in migraine. Nat Rev Neurosci. 2011;12(10):570–584. doi: 10.1038/nrn3057.
  16. Charles A. Advances in the basic and clinical science of migraine. Ann Neurol. 2009;65(5):491–498. doi: 10.1002/ana.21691.
  17. Pietrobon D, Striessnig J. Neurobiology of migraine. Nat Rev Neurosci. 2003;4(5):386–398. doi: 10.1038/nrn1102.
  18. Karatas H, Erdener SE, Gursoy-Ozdemir Y, Lule S, Eren-Koçak E, Sen ZD, Dalkara T. Spreading depression triggers headache by activating neuronal Panx1 channels. Science. 2013 Mar 01;339(6123):1092-5
  19. Andreou AP, Edvinsson L. Mechanisms of migraine as a chronic evolutive condition. J Headache Pain. 2019 Dec 23;20(1):117.
  20. Bolay H, Reuter U, Dunn AK, Huang Z, Boas DA, Moskowitz MA. Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model. Nat Med. 2002 Feb;8(2):136-42.
  21. Gursoy-Ozdemir Y, Qiu J, Matsuoka N, Bolay H, Bermpohl D, Jin H, Wang X, Rosenberg GA, Lo EH, Moskowitz MA. Cortical spreading depression activates and upregulates MMP-9. J Clin Invest. 2004 May;113(10):1447-55.
  22. Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2017;97(2):553-622.
  23. Akerman S, Holland PR, Goadsby PJ. Diencephalic and brainstem mechanisms in migraine. Nature Reviews Neuroscience. 2011 Oct;12(10):570-84.
  24. Moskowitz MA. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends PharmacolSci 1992; 13:307-11.
  25. Stoll, A. “Zur Kenntnis der Mutterkornalkaloide.” Verhand der Schweiz Naturf Ges 190 (1920): 221.
  26. Maier HW. L’ergotamine, inhibiteur du sympathiqueétudié en clinique, commemoyend’explorationetcomme agent thérapeutique. Rev Neurol. 1926;33:1104–8.
  27. Tfelt-Hansen P, Saxena PR, Dahlof C, et al. Ergotamine in the acute treatment of migraine: a review and European consensus. 2000;123(Pt 1):9–18. doi: 10.1093/brain/123.1.9.
  28. Sanders SW, Haering N, Mosberg H, Jaeger H. Pharmacokinetics of ergotamine in healthy volunteers following oral and rectal dosing. Eur J ClinPharmacol. 1986;30(3):331–334. doi: 10.1007/BF00541538.
  29. Tfelt-Hansen PJE. Ergotamine. In: Olesen JT-HP, Welch KM, editors. The headaches. New York: Raven Press; 1993. pp. 313–322.
  30. Johnston BM, Saxena PR. The effect of ergotamine on tissue blood flow and the arteriovenous shunting of radioactive microspheres in the head. Br J Pharmacol. 1978;63(3):541–549. doi: 10.1111/j.1476-5381.1978.tb07810.x.
  31. De Vries P, Villalon CM, Heiligers JP, Saxena PR. Characterization of 5-HT receptors mediating constriction of porcine carotid arteriovenous anastomoses; involvement of 5-HT1B/1D and novel receptors. Br J Pharmacol. 1998;123(8):1561–1570. doi: 10.1038/sj.bjp.0701770.
  32. Cortijo J, Marti-Cabrera M, Bernabeu E, et al. Characterization of 5-HT receptors on human pulmonary artery and vein: functional and binding studies. Br J Pharmacol. 1997;122(7):1455–1463. doi: 10.1038/sj.bjp.0701509.
  33. MaassenVanDenBrink A, Reekers M, Bax WA, Ferrari MD, Saxena PR. Coronary side-effect potential of current and prospective antimigraine drugs. 1998;98(1):25–30. doi: 10.1161/01.CIR.98.1.25.
  34. Galer BS, Lipton RB, Solomon S, Newman LC, Spierings EL. Myocardial ischemia related to ergot alkaloids: a case report and literature review. 1991;31(7):446–450. doi: 10.1111/j.1526-4610.1991.hed3107446.x.
  35. Saxena PR, Ferrari MD. 5-HT(1)-like receptor agonists and the pathophysiology of migraine. Trends Pharmacol Sci. 1989;10(5):200–204. doi: 10.1016/0165-6147(89)90238-1.
  36. Hargreaves RJ, Shepheard SL. Pathophysiology of migraine—new insights. Can J Neurol Sci. 1999;26(Suppl. 3):S12–S19. doi: 10.1017/S0317167100000147.
  37. Ahn AH, Basbaum AI. Where do triptans act in the treatment of migraine? 2005;115(1-2):1–4. doi: 10.1016/j.pain.2005.03.008.
  38. Alahurula, V.; Myllyla, V. V.; Hokkanen, E.; Tokola, O. Tolfenamic acid and ergotamine abuse. Headache 1981, 21, 240–242.
  39. Mathew, N. T. Amelioration of ergotamine withdrawal symptoms with naproxen. Headache 1987, 27, 130–133.
  40. Havankakanniainen, H. Treatment of acute migraine attack—Ibuprofen and placebo compared. Headache 1989, 29, 507–509.
  41. Sandrini, G.; Franchini, S.; Lanfranchi, S.; Granella, F.; Manzoni, G. C.; Nappi, G. Effectiveness of ibuprofen-arginine in the treatment of acute migraine attacks. J. Clin. Pharm. Res. 1998, 18, 145–150.
  42. Kellstein, D. E.; Lipton, R. B.; Geetha, R.; Koronkiewicz, K.; Evans, F. T.; Stewart, W. F.; Wilkes, K.; Furey, S. A.; Subramanian, T.; Cooper, S. A. Evaluation of a novel solubilized formulation of ibuprofen in the treatment of migraine headache: A randomized, double-blind, placebo-controlled, dose-ranging study. Cephalalgia2000, 20, 233–243.
  43. Codispoti, J. R.; Prior, M. J.; Fu, M.; Harte, C. M.; Nelson, E. B. Efficacy of nonprescription doses of ibuprofen for treating migraine headache. A randomized controlled trial. Headache 2001, 41, 665–679.
  44. Misra, U. K.; Kalita, J.; Yadav, R. K. Rizatriptan ibuprofen in migraine: A randomised placebo-controlled trial. J. Headache Pain 2007, 8, 175–179.
  45. Diener, H. C.; Bussone, G.; de Liano, H.; Eikermann, A.; Englert, R.; Floeter, T.; Gallai, V.; Gobel, H.; Hartung, E.; Jimenez, M. D.; Lange, R.; Manzoni, G. C.; Mueller-Schwefe, G.; Nappi, G.; Pinessi, L.; Prat, J.; Puca, F. M.; Titus, F.; Voelker, M. Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks. Cephalalgia2004, 24, 947–954.

Regular Issue Subscription Review Article
Volume 14
Issue 01
Received March 11, 2024
Accepted March 28, 2024
Published April 20, 2024